Cytochrome P450-3A phenotyping using midazolam is not altered by OATP1B1 polymorphisms

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 388-

  Ziesenitz, V C ^a   Weiss, J ^a   Haefeli, W E ^a   Mikus, G ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A; ERYTHROMYCIN; MIDAZOLAM; MIDAZOLAM MALEATE; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 1 B1; UNCLASSIFIED DRUG;

DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; DRUG TRANSPORT; FEMALE; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LETTER; MALE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ERYTHROMYCIN; FEMALE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 84876680780     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.46     Document Type: Letter

References (4)

1. Lancaster, C.S. et al. OATP1B1 polymorphism as a determinant of erythromycin disposition. Clin. Pharmacol. Ther. 92, 642-650 (2012).
2. Benet, L.Z. A step closer to personalized chemotherapy: consideration of the infuence of genetic variation in hepatic uptake transporters on the metabolism of CyP3A substrates. Clin. Pharmacol. Ther. 92, 551-552 (2012).
3. Franke, R.M., Baker, S.D., Mathijssen, R.H., Schuetz, E.G. & Sparreboom, A. Infuence of solute carriers on the pharmacokinetics of CyP3A4 probes. Clin. Pharmacol. Ther. 84, 704-709 (2008).
4. Katzenmaier, S., Markert, C., Riedel, K.D., Burhenne, J., Haefeli, W.E. & Mikus, G. Determining the time course of CyP3A inhibition by potent reversible and irreversible CyP3A inhibitors using a limited sampling strategy. Clin. Pharmacol. Ther. 90, 666-673 (2011).